Latest Breaking News On - மிட்‌ஸ்யூபீஶி தனபெ பார்மா ஹோல்டிங்ஸ் அமெரிக்கா - Page 1 : comparemela.com

Share this article Share this article JERSEY CITY, N.J., May 12, 2021 /PRNewswire/  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA ® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS). The analysis will be presented during the 2021 European Network to Cure ALS (ENCALS) Meeting, being held virtually May 12-14. Initial insights shared with the scientific community during ENCALS are a part of our wide-ranging efforts to compile real-world data that can be used to learn as much as possible about the clinical experience of RADICAVA, said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. We utilized a rigorous statistical methodology to comprehensively assess more than two years of administrative claims data for our therapy. Analysis is still ongoing, and we look forward to sharing more details about the methodology

United statesCh ungch ong namdoSouth koreaGustavoa suarez zambranoDebbie etchisonTanabe pharmaMitsubishi tanabe pharma america incMitsubishi tanabe pharma corporationDrug administrationOverview of mitsubishi tanabe pharma corporationEuropean network to cureMitsubishi tanabe pharma holdings america incMitsubishi tanabe pharma americaVice presidentMedical affairsPrescribing information